Business, energy, technology, markets and global industry news from Business News Today

PSMA

PharmaDeviceNews PSMA
Representative image of a clinician reviewing prostate cancer imaging in a modern nuclear medicine setting, reflecting Convergent Therapeutics’ CONV01-α Phase 2 data and the growing race to develop Actinium-225 radiopharmaceuticals for post-Lu-PSMA metastatic prostate cancer.
Pharma & Biotech

Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?

CONV01-α is targeting the post-Lu-PSMA prostate cancer gap. Convergent now faces the Phase 3 test that will decide its real value.

Read More
Pharma & Biotech

Convergent Therapeutics heads to ASCO 2026 with Phase 2 CONV01-alpha data in Lu-PSMA pretreated prostate cancer

Convergent Therapeutics will present Phase 2 CONV01-alpha data at ASCO 2026. Find out what this could mean for post-Lu-PSMA prostate cancer care.

Read More
Pharma & Biotech

How JANX014 expands Janux Therapeutics’ tumor-activated platform strategy in prostate cancer immunotherapy

Janux Therapeutics advances JANX014 into Phase 1 for prostate cancer. Discover what this means for PSMA therapies and T cell engager safety.

Read More